Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up.
Nides, Mitchell
Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. [electronic resource] - Archives of internal medicine - 1561-8 p. digital
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
0003-9926
10.1001/archinte.166.15.1561 doi
Adolescent
Adult
Aged
Benzazepines--adverse effects
Bupropion--therapeutic use
Dopamine Uptake Inhibitors--therapeutic use
Double-Blind Method
Female
Follow-Up Studies
Health Status
Humans
Male
Middle Aged
Nicotinic Agonists--adverse effects
Nicotinic Antagonists--adverse effects
Quinoxalines--adverse effects
Smoking Cessation--methods
Tobacco Use Disorder--drug therapy
Treatment Outcome
Varenicline
Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. [electronic resource] - Archives of internal medicine - 1561-8 p. digital
Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
0003-9926
10.1001/archinte.166.15.1561 doi
Adolescent
Adult
Aged
Benzazepines--adverse effects
Bupropion--therapeutic use
Dopamine Uptake Inhibitors--therapeutic use
Double-Blind Method
Female
Follow-Up Studies
Health Status
Humans
Male
Middle Aged
Nicotinic Agonists--adverse effects
Nicotinic Antagonists--adverse effects
Quinoxalines--adverse effects
Smoking Cessation--methods
Tobacco Use Disorder--drug therapy
Treatment Outcome
Varenicline